Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for INCY

Stock Name	Incyte Corporation
Ticker	INCY(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US45337C1027
LEI	549300Z4WN6JVZ3T4680

Show aggregate INCY holdings

News associated with INCY

Incyte Reaches Analyst Target Price: In recent trading, shares of Incyte Corporation (Symbol: INCY) have crossed above the average analyst 12-month target price of $84.18, changing hands for $84.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v - 2025-09-18 08:17:02
Incyte Reports Encouraging 24-Week Results From Phase 3 STOP-HS Program Of Povorcitinib: (RTTNews) - Incyte Corporation (INCY) on Wednesday announced encouraging 24-week data from the pivotal Phase 3 STOP-HS program evaluating povorcitinib in adults with hidradenitis suppurativa (HS). - 2025-09-17 03:26:09
Incyte Corporation (NASDAQ:INCY) Short Interest Update: Incyte Corporation (NASDAQ:INCY – Get Free Report) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totaling 9,600,000 shares, an increase of 29.4% from the July 31st total of 7,420,000 shares. Based on an average trading volume of 1,860,000 shares, the […] - 2025-09-11 04:51:36
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of “Hold” from Analysts: Incyte Corporation (NASDAQ:INCY – Get Free Report) has been assigned a consensus recommendation of “Hold” from the eighteen analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating on the company. The […] - 2025-08-26 02:32:54
Incyte (NASDAQ:INCY) Given New $73.00 Price Target at JPMorgan Chase & Co.: Incyte (NASDAQ:INCY – Free Report) had its price objective increased by JPMorgan Chase & Co. from $67.00 to $73.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. A number of other research firms also recently commented on INCY. Citigroup upped their price objective on […] - 2025-08-25 03:08:46
LABU, INCY, UTHR, REGN: ETF Outflow Alert: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Charles Schwab Investment Management Inc. Purchases 38,962 Shares of Incyte Corporation (NASDAQ:INCY): Charles Schwab Investment Management Inc. raised its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 2.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,682,029 shares of the biopharmaceutical company’s stock after purchasing an additional 38,962 […] - 2025-08-13 05:43:01
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Citigroup Raises Incyte (NASDAQ:INCY) Price Target to $103.00: Incyte (NASDAQ:INCY – Get Free Report) had its price objective lifted by equities researchers at Citigroup from $88.00 to $103.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s target price suggests a potential upside of 37.54% from the […] - 2025-08-01 04:32:55
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of “Hold” from Analysts: Shares of Incyte Corporation (NASDAQ:INCY – Get Free Report) have earned a consensus rating of “Hold” from the eighteen research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, twelve have given a hold recommendation and five have assigned a buy recommendation to the […] - 2025-08-01 03:04:43
Incyte Reaches Analyst Target Price: In recent trading, shares of Incyte Corporation (Symbol: INCY) have crossed above the average analyst 12-month target price of $76.09, changing hands for $77.38/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v - 2025-07-30 10:12:59
Mutual of America Capital Management LLC Sells 478 Shares of Incyte Corporation (NASDAQ:INCY): Mutual of America Capital Management LLC lessened its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 2.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,719 shares of the biopharmaceutical company’s stock after selling 478 shares during the quarter. […] - 2025-07-22 08:02:58
Incyte Corporation (NASDAQ:INCY) Shares Sold by Ballentine Partners LLC: Ballentine Partners LLC trimmed its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 12.2% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 4,686 shares of the biopharmaceutical company’s stock after selling 649 shares during the quarter. Ballentine Partners LLC’s holdings in Incyte were worth $284,000 at the end of the most recent […] - 2025-07-17 05:12:56
Cerity Partners LLC Has $8.04 Million Stock Position in Incyte Corporation (NASDAQ:INCY): Cerity Partners LLC lifted its holdings in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 103.5% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 132,703 shares of the biopharmaceutical company’s stock after buying an additional 67,495 shares during the period. Cerity Partners LLC owned […] - 2025-07-16 05:40:51
Incyte (NASDAQ:INCY) Price Target Cut to $67.00 by Analysts at JPMorgan Chase & Co.: Incyte (NASDAQ:INCY – Get Free Report) had its price objective decreased by equities research analysts at JPMorgan Chase & Co. from $68.00 to $67.00 in a report released on Monday,Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential downside of […] - 2025-07-16 04:26:52
Sheila A. Denton Sells 599 Shares of Incyte Corporation (NASDAQ:INCY) Stock: Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Sheila A. Denton sold 599 shares of the company’s stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $68.61, for a total value of $41,097.39. Following the completion of the sale, the executive vice president owned 26,504 […] - 2025-07-09 06:12:52
Incyte Corporation (NASDAQ:INCY) EVP Barry P. Flannelly Sells 10,903 Shares of Stock: Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Barry P. Flannelly sold 10,903 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $68.15, for a total transaction of $743,039.45. Following the sale, the executive vice president directly owned 39,744 shares of the […] - 2025-07-08 06:54:44
Incyte Corporation (NASDAQ:INCY) EVP Sells $587,248.55 in Stock: Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Vijay K. Iyengar sold 8,617 shares of the company’s stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $68.15, for a total transaction of $587,248.55. Following the completion of the sale, the executive vice president directly owned 37,701 shares […] - 2025-07-08 06:20:54
Incyte Corporation (NASDAQ:INCY) Shares Sold by Vontobel Holding Ltd.: Vontobel Holding Ltd. trimmed its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 16.8% in the first quarter, Holdings Channel.com reports. The institutional investor owned 7,875 shares of the biopharmaceutical company’s stock after selling 1,592 shares during the quarter. Vontobel Holding Ltd.’s holdings in Incyte were worth $477,000 as of its most recent filing […] - 2025-07-08 04:46:50
Sumitomo Mitsui Trust Group Inc. Purchases 25,844 Shares of Incyte Corporation (NASDAQ:INCY): Sumitomo Mitsui Trust Group Inc. increased its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 5.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 473,186 shares of the biopharmaceutical company’s stock after purchasing an additional 25,844 shares […] - 2025-07-03 05:25:07
Incyte Corporation (NASDAQ:INCY) Shares Purchased by Chevy Chase Trust Holdings LLC: Chevy Chase Trust Holdings LLC raised its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 0.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,241 shares of the biopharmaceutical company’s stock after purchasing an additional 334 shares during the quarter. […] - 2025-06-27 05:36:52
Janney Montgomery Scott LLC Boosts Stock Position in Incyte Corporation (NASDAQ:INCY): Janney Montgomery Scott LLC grew its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 10.2% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 29,793 shares of the biopharmaceutical company’s stock after purchasing an additional 2,746 shares during the period. Janney Montgomery Scott LLC’s holdings in Incyte were worth $1,804,000 as of its […] - 2025-06-27 04:26:49
State of Alaska Department of Revenue Purchases 590 Shares of Incyte Corporation (NASDAQ:INCY): State of Alaska Department of Revenue lifted its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 3.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,824 shares of the biopharmaceutical company’s stock after acquiring an additional 590 shares […] - 2025-06-26 05:56:50
Kentucky Retirement Systems Insurance Trust Fund Makes New Investment in Incyte Corporation (NASDAQ:INCY): Kentucky Retirement Systems Insurance Trust Fund bought a new stake in Incyte Corporation (NASDAQ:INCY – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,624 shares of the biopharmaceutical company’s stock, valued at approximately $280,000. A number […] - 2025-06-26 05:03:09
Incyte Corporation (NASDAQ:INCY) Shares Acquired by Wealth Enhancement Advisory Services LLC: Wealth Enhancement Advisory Services LLC lifted its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 66.5% during the 1st quarter, HoldingsChannel.com reports. The fund owned 79,735 shares of the biopharmaceutical company’s stock after acquiring an additional 31,851 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Incyte were worth $4,828,000 […] - 2025-06-26 04:30:52
Assenagon Asset Management S.A. Has $536,000 Stock Position in Incyte Corporation (NASDAQ:INCY): Assenagon Asset Management S.A. raised its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 37.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,846 shares of the biopharmaceutical company’s stock after acquiring an additional 2,418 shares during the period. […] - 2025-06-20 04:54:50
Incyte Corporation (NASDAQ:INCY) Shares Sold by Exchange Traded Concepts LLC: Exchange Traded Concepts LLC lowered its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 41.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,117 shares of the biopharmaceutical company’s stock after selling 12,867 shares during the period. Exchange Traded Concepts […] - 2025-06-19 05:43:03
Fifth Third Bancorp Has $551,000 Holdings in Incyte Corporation (NASDAQ:INCY): Fifth Third Bancorp raised its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 2.0% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 9,103 shares of the biopharmaceutical company’s stock after acquiring an additional 179 shares during the quarter. Fifth Third Bancorp’s holdings in Incyte were worth $551,000 at the end of […] - 2025-06-18 04:56:49
Incyte (NASDAQ:INCY) Raised to “Buy” at Stifel Nicolaus: Incyte (NASDAQ:INCY – Get Free Report) was upgraded by equities researchers at Stifel Nicolaus from a “hold” rating to a “buy” rating in a research report issued on Monday, MarketBeat reports. The brokerage currently has a $107.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $75.00. Stifel Nicolaus’ price […] - 2025-06-18 02:22:54
Stocks Settle Higher on Possible De-Escalation of Israel-Iran War: The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.94%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.42%. June E-mini S&P futures (ESM25 ) are up +1.00%, and June E-mini Nasdaq futures... - 2025-06-17 13:23:43

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) INCY holdings

Date	Number of INCY Shares Held	Base Market Value of INCY Shares	Local Market Value of INCY Shares	Change in INCY Shares Held	Change in INCY Base Value	Current Price per INCY Share Held	Previous Price per INCY Share Held
2025-11-11 (Tuesday)	126,671	USD 13,700,735	USD 13,700,735	0	USD 276,142	USD 108.16	USD 105.98
2025-11-10 (Monday)	126,671	USD 13,424,593	USD 13,424,593	324	USD 34,338	USD 105.98	USD 105.98
2025-11-07 (Friday)	126,347	USD 13,390,255	USD 13,390,255	0	USD 98,551	USD 105.98	USD 105.2
2025-11-06 (Thursday)	126,347	USD 13,291,704	USD 13,291,704	324	USD -28,927	USD 105.2	USD 105.7
2025-11-05 (Wednesday)	126,023	USD 13,320,631	USD 13,320,631	0	USD 350,344	USD 105.7	USD 102.92
2025-11-04 (Tuesday)	126,023	USD 12,970,287	USD 12,970,287	325	USD 203,141	USD 102.92	USD 101.57
2025-11-03 (Monday)	125,698	USD 12,767,146	USD 12,767,146	0	USD 1,016,897	USD 101.57	USD 93.48
2025-10-31 (Friday)	125,698	USD 11,750,249	USD 11,750,249	0	USD 111,871	USD 93.48	USD 92.59
2025-10-30 (Thursday)	125,698	USD 11,638,378	USD 11,638,378	1,625	USD 449,475	USD 92.59	USD 90.18
2025-10-29 (Wednesday)	124,073	USD 11,188,903	USD 11,188,903	1,041	USD -86,980	USD 90.18	USD 91.65
2025-10-28 (Tuesday)	123,032	USD 11,275,883	USD 11,275,883	0	USD -175,936	USD 91.65	USD 93.08
2025-10-27 (Monday)	123,032	USD 11,451,819	USD 11,451,819	0	USD 221,458	USD 93.08	USD 91.28

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of INCY by Blackrock for IE00BDZVHG35

Show aggregate share trades of INCY

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 324 108.810 104.070 104.544 USD 33,872 71.33
2025-11-06 BUY 324 106.430 103.075 103.410 USD 33,505 70.96
2025-11-04 BUY 325 103.860 100.020 100.404 USD 32,631 70.60
2025-10-30 BUY 1,625 94.620 91.190 91.533 USD 148,741 70.19
2025-10-29 BUY 1,041 90.180 94.420 93.996 USD 97,850 70.08
2025-10-22 SELL -1,296 88.060 88.210 88.195 USD -114,301 69.49 Loss of -24,242 on sale
2025-10-20 BUY 648 86.170 87.950 87.772 USD 56,876 69.29
2025-10-17 BUY 1,619 87.570 88.540 88.443 USD 143,189 69.19
2025-10-15 BUY 2,584 88.150 88.490 88.456 USD 228,570 69.08
2025-10-03 BUY 2,247 86.850 86.980 86.967 USD 195,415 68.87
2025-10-02 BUY 321 86.280 88.660 88.422 USD 28,383 68.77
2025-09-30 BUY 642 84.810 85.310 85.260 USD 54,737 68.57
2025-09-26 BUY 642 82.700 82.950 82.925 USD 53,238 68.39
2025-09-25 BUY 642 81.660 84.450 84.171 USD 54,038 68.31
2025-09-18 BUY 333 86.000 86.070 86.063 USD 28,659 68.20
2025-09-17 BUY 1,002 84.800 85.980 85.862 USD 86,034 68.10
2025-09-11 SELL -334 86.170 87.100 87.007 USD -29,060 67.88 Loss of -6,387 on sale
2025-09-10 BUY 668 86.250 86.940 86.871 USD 58,030 67.77
2025-07-17 SELL -668 68.940 69.650 69.579 USD -46,479 67.65 Loss of -1,290 on sale
2025-07-16 BUY 1,139 69.230 69.420 69.401 USD 79,048 67.64
2025-07-11 SELL -2,648 68.590 69.970 69.832 USD -184,915 67.61 Loss of -5,881 on sale
2025-07-02 BUY 18,205 68.170 69.100 69.007 USD 1,256,272 67.58
2025-06-25 BUY 662 67.550 69.140 68.981 USD 45,665 67.54
2025-06-20 BUY 2,451 68.460 69.190 69.117 USD 169,406 67.53
2025-06-13 BUY 394 67.750 68.960 68.839 USD 27,123 67.48
2025-06-11 BUY 642 68.850 70.360 70.209 USD 45,074 67.46
2025-06-10 BUY 642 70.070 70.980 70.889 USD 45,511 67.44
2025-06-04 SELL -321 67.420 68.450 68.347 USD -21,939 67.41 Loss of -301 on sale
2025-04-23 BUY 321 58.000 59.010 58.909 USD 18,910 68.93
2025-04-10 SELL -2,568 55.170 58.330 58.014 USD -148,980 70.08 Profit of 30,992 on sale
2025-04-08 SELL -321 56.970 61.470 61.020 USD -19,587 70.36 Profit of 2,999 on sale
2025-04-07 SELL -321 60.290 61.060 60.983 USD -19,576 70.48 Profit of 3,048 on sale
2025-04-04 SELL -1,605 60.580 63.570 63.271 USD -101,550 70.60 Profit of 11,756 on sale
2025-04-01 BUY 2,780 60.910 62.000 61.891 USD 172,057 70.81
2025-03-31 SELL -948 60.550 60.810 60.784 USD -57,623 70.94 Profit of 9,625 on sale
2025-03-21 BUY 4,199 61.920 62.330 62.289 USD 261,552 71.68
2025-03-14 SELL -4,832 67.860 68.120 68.094 USD -329,030 72.35 Profit of 20,557 on sale
2025-03-07 SELL -604 70.790 72.810 72.608 USD -43,855 72.60 Loss of -8 on sale
2025-03-04 SELL -302 69.680 70.000 69.968 USD -21,130 72.73 Profit of 833 on sale
2025-02-25 BUY 604 74.400 76.240 76.056 USD 45,938 72.69
2025-02-19 SELL -302 70.160 71.430 71.303 USD -21,534 72.75 Profit of 437 on sale
2025-02-13 BUY 906 70.010 72.690 72.422 USD 65,614 72.93
2025-02-12 BUY 302 69.050 69.100 69.095 USD 20,867 73.01
2025-02-11 BUY 1,208 66.330 68.690 68.454 USD 82,692 73.14
2025-01-02 BUY 350 69.530 70.270 70.196 USD 24,569 73.19
2024-12-30 SELL -11,025 68.420 68.870 68.825 USD -758,796 73.33 Profit of 49,674 on sale
2024-11-18 SELL -4,965 76.970 77.010 77.006 USD -382,335 73.13 Loss of -19,241 on sale
2024-11-08 SELL -331 83.380 83.950 83.893 USD -27,769 71.87 Loss of -3,981 on sale
2024-10-30 BUY 384 73.930 74.600 74.533 USD 28,621 66.52
2024-10-21 SELL -330 65.270 66.550 66.422 USD -21,919 0.00 Loss of -21,919 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	324	108.810	104.070	104.544	USD 33,872	71.33
2025-11-06	BUY	324	106.430	103.075	103.410	USD 33,505	70.96
2025-11-04	BUY	325	103.860	100.020	100.404	USD 32,631	70.60
2025-10-30	BUY	1,625	94.620	91.190	91.533	USD 148,741	70.19
2025-10-29	BUY	1,041	90.180	94.420	93.996	USD 97,850	70.08
2025-10-22	SELL	-1,296	88.060	88.210	88.195	USD -114,301	69.49 Loss of -24,242 on sale
2025-10-20	BUY	648	86.170	87.950	87.772	USD 56,876	69.29
2025-10-17	BUY	1,619	87.570	88.540	88.443	USD 143,189	69.19
2025-10-15	BUY	2,584	88.150	88.490	88.456	USD 228,570	69.08
2025-10-03	BUY	2,247	86.850	86.980	86.967	USD 195,415	68.87
2025-10-02	BUY	321	86.280	88.660	88.422	USD 28,383	68.77
2025-09-30	BUY	642	84.810	85.310	85.260	USD 54,737	68.57
2025-09-26	BUY	642	82.700	82.950	82.925	USD 53,238	68.39
2025-09-25	BUY	642	81.660	84.450	84.171	USD 54,038	68.31
2025-09-18	BUY	333	86.000	86.070	86.063	USD 28,659	68.20
2025-09-17	BUY	1,002	84.800	85.980	85.862	USD 86,034	68.10
2025-09-11	SELL	-334	86.170	87.100	87.007	USD -29,060	67.88 Loss of -6,387 on sale
2025-09-10	BUY	668	86.250	86.940	86.871	USD 58,030	67.77
2025-07-17	SELL	-668	68.940	69.650	69.579	USD -46,479	67.65 Loss of -1,290 on sale
2025-07-16	BUY	1,139	69.230	69.420	69.401	USD 79,048	67.64
2025-07-11	SELL	-2,648	68.590	69.970	69.832	USD -184,915	67.61 Loss of -5,881 on sale
2025-07-02	BUY	18,205	68.170	69.100	69.007	USD 1,256,272	67.58
2025-06-25	BUY	662	67.550	69.140	68.981	USD 45,665	67.54
2025-06-20	BUY	2,451	68.460	69.190	69.117	USD 169,406	67.53
2025-06-13	BUY	394	67.750	68.960	68.839	USD 27,123	67.48
2025-06-11	BUY	642	68.850	70.360	70.209	USD 45,074	67.46
2025-06-10	BUY	642	70.070	70.980	70.889	USD 45,511	67.44
2025-06-04	SELL	-321	67.420	68.450	68.347	USD -21,939	67.41 Loss of -301 on sale
2025-04-23	BUY	321	58.000	59.010	58.909	USD 18,910	68.93
2025-04-10	SELL	-2,568	55.170	58.330	58.014	USD -148,980	70.08 Profit of 30,992 on sale
2025-04-08	SELL	-321	56.970	61.470	61.020	USD -19,587	70.36 Profit of 2,999 on sale
2025-04-07	SELL	-321	60.290	61.060	60.983	USD -19,576	70.48 Profit of 3,048 on sale
2025-04-04	SELL	-1,605	60.580	63.570	63.271	USD -101,550	70.60 Profit of 11,756 on sale
2025-04-01	BUY	2,780	60.910	62.000	61.891	USD 172,057	70.81
2025-03-31	SELL	-948	60.550	60.810	60.784	USD -57,623	70.94 Profit of 9,625 on sale
2025-03-21	BUY	4,199	61.920	62.330	62.289	USD 261,552	71.68
2025-03-14	SELL	-4,832	67.860	68.120	68.094	USD -329,030	72.35 Profit of 20,557 on sale
2025-03-07	SELL	-604	70.790	72.810	72.608	USD -43,855	72.60 Loss of -8 on sale
2025-03-04	SELL	-302	69.680	70.000	69.968	USD -21,130	72.73 Profit of 833 on sale
2025-02-25	BUY	604	74.400	76.240	76.056	USD 45,938	72.69
2025-02-19	SELL	-302	70.160	71.430	71.303	USD -21,534	72.75 Profit of 437 on sale
2025-02-13	BUY	906	70.010	72.690	72.422	USD 65,614	72.93
2025-02-12	BUY	302	69.050	69.100	69.095	USD 20,867	73.01
2025-02-11	BUY	1,208	66.330	68.690	68.454	USD 82,692	73.14
2025-01-02	BUY	350	69.530	70.270	70.196	USD 24,569	73.19
2024-12-30	SELL	-11,025	68.420	68.870	68.825	USD -758,796	73.33 Profit of 49,674 on sale
2024-11-18	SELL	-4,965	76.970	77.010	77.006	USD -382,335	73.13 Loss of -19,241 on sale
2024-11-08	SELL	-331	83.380	83.950	83.893	USD -27,769	71.87 Loss of -3,981 on sale
2024-10-30	BUY	384	73.930	74.600	74.533	USD 28,621	66.52
2024-10-21	SELL	-330	65.270	66.550	66.422	USD -21,919	0.00 Loss of -21,919 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of INCY

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	321,923	395	451,110	71.4%
2025-09-18	244,947	1,423	469,747	52.1%
2025-09-17	277,858	779	546,953	50.8%
2025-09-16	359,781	946	576,379	62.4%
2025-09-15	347,453	4	582,228	59.7%
2025-09-12	353,040	0	631,534	55.9%
2025-09-11	448,733	3,894	739,701	60.7%
2025-09-10	490,727	248	671,932	73.0%
2025-09-09	515,395	1,822	682,791	75.5%
2025-09-08	308,184	119	479,828	64.2%
2025-09-05	256,719	2,505	512,049	50.1%
2025-09-04	422,624	1,507	834,717	50.6%
2025-09-03	381,679	7,777	624,922	61.1%
2025-09-02	547,120	15,396	816,267	67.0%
2025-08-29	148,294	262	304,427	48.7%
2025-08-28	164,008	0	347,480	47.2%
2025-08-27	248,926	453	513,401	48.5%
2025-08-26	365,130	6	709,320	51.5%
2025-08-25	478,130	1,306	642,319	74.4%
2025-08-22	344,352	2,023	596,301	57.7%
2025-08-21	198,729	4,881	335,301	59.3%
2025-08-20	351,699	3,977	555,345	63.3%
2025-08-19	343,110	3,146	574,328	59.7%
2025-08-18	366,124	4,996	653,103	56.1%
2025-08-15	480,885	8,035	625,797	76.8%
2025-08-14	593,554	36,654	806,068	73.6%
2025-08-13	845,181	98,160	1,257,503	67.2%
2025-08-12	462,896	42,208	678,689	68.2%
2025-08-11	385,211	696	595,892	64.6%
2025-08-08	248,925	738	426,187	58.4%
2025-08-07	268,864	929	420,486	63.9%
2025-08-06	554,642	891	731,484	75.8%
2025-08-05	361,687	2,092	623,879	58.0%
2025-08-04	338,005	1,464	519,150	65.1%
2025-08-01	414,814	828	572,879	72.4%
2025-07-31	570,845	6,148	777,417	73.4%
2025-07-30	471,303	14,166	881,194	53.5%
2025-07-29	966,640	10,581	1,593,701	60.7%
2025-07-28	382,236	62	625,510	61.1%
2025-07-25	216,967	49	422,990	51.3%
2025-07-24	348,276	23	528,517	65.9%
2025-07-23	297,903	583	487,297	61.1%
2025-07-22	267,987	172	446,489	60.0%
2025-07-21	223,626	380	406,729	55.0%
2025-07-18	241,218	108	471,589	51.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE